Namita A. Goyal

Namita A. Goyal

Neurology | Neuromusculoskeletal Medicine
200 South Manchester Avenue
Suite 110
Orange, CA 92868

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications

Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Journal: Nature
Published: March 19, 2026

A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study.

A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study.

Journal: Journal of neuromuscular diseases
Published: February 06, 2026

Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS.

Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS.

Journal: Biomedicines
Published: September 18, 2025

Multicenter Expanded Access Protocol for Research Through Access to Trehalose in People With Amyotrophic Lateral Sclerosis.

Multicenter Expanded Access Protocol for Research Through Access to Trehalose in People With Amyotrophic Lateral Sclerosis.

Journal: Muscle & nerve
Published: April 21, 2025

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

Journal: JAMA
Published: March 11, 2025

Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

Journal: JAMA
Published: March 11, 2025

Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

Journal: JAMA network open
Published: February 17, 2025

Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Journal: Nature
Published: February 04, 2025

Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Journal: Nature
Published: February 04, 2025

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.

Journal: JAMA neurology
Published: August 28, 2024

The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis.

The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis.

Journal: Biomedicines
Published: August 20, 2024

The Dermatomyositis Disease Symptom Questionnaire (DM-DSQ): A Measure to Assess the Patient Experience of Dermatomyositis Symptoms.

The Dermatomyositis Disease Symptom Questionnaire (DM-DSQ): A Measure to Assess the Patient Experience of Dermatomyositis Symptoms.

Journal: The Journal of rheumatology
Published: July 08, 2024
Showing 1-12 of 71

Last Updated: 09/26/2026